Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice
Metabolic syndrome is a chronic-metabolic disease caused by a variety of factors, including high peripheral blood insulin levels and insulin resistance. It has been reported that GLP-1 could regulate insulin resistance. It is not known whether and how GLP-1 protects from fat-induced inflammation and immune changes. We investigated if GLP-1 alters the populations of fat-induced inflammation and immune cells and the related mechanism.
We obtained obese C57BL/6J mice by feeding them high-fat food, then treated the obese mice with GLP-1+ high-fat diet (G + Hi), normal chow diet (Nor), or high-fat diet (Hi) (n = 20 for each group) for 8 weeks. The GLP-1 receptor−/− B6 group were fed with HFD for 8 weeks (GLP-1R KO + Hi). In vivo and in vitro experiments were conducted on mice immune cells to investigate the effects of GLP-1 on the changes of the immune components and functions in obesity.
We found that GLP-1 could efficiently change the CD4+ T subsets and level of cytokines in high-fat-induced mice by GLP-1 receptor. Further, these changes were correlated with a reduction in fat content and serum lipid level. Interestingly, GLP-1 could enhance the function of Tregs in vitro.
Our data showed that GLP-1 has an important role in shaping the CD4+ T population in high-fat-diet-induced mice by GLP-1 receptor, possibly providing a new target for the treatment of metabolic syndrome.
KeywordsObesity Immune GLP-1 Metabolic syndrome
This work was supported by grants from the Key Research and Development Program of Shandong Province (No. 2016GSF201012) and the Natural Science Foundation of Shandong Province (No. BS2015YY011) and the National Natural Science Foundation (No. 81500631).
LS conceived the project. SS and LS designed the experiments. SS analyzed the data and conducted experiments. SS wrote and edited the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 17.P. Almgren, A. Lindqvist, U. Krus, et al. Genetic determinants of circulating GIP and GLP-1 concentrations. JCI Insight. 2(21), e93306 (2017)Google Scholar
- 19.S. Baba, M. Iwasa, K. Higashi et al. Antidiabetic drug alogliptin protects the heart against ischemia-reperfusion injury through GLP-1 receptor-dependent and receptor-independent pathways involving nitric oxide production in rabbits. J. Cardiovasc. Pharmacol. 70(6), 382–389 (2017)PubMedGoogle Scholar